PMID- 25877382
OWN - NLM
STAT- MEDLINE
DCOM- 20160624
LR  - 20191113
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 15
IP  - 3
DP  - 2015
TI  - Relationship between Fatty Acid Habitual Intake and Early Inflammation Biomarkers 
      in Individuals with and without Type 2 Diabetes in Mexico.
PG  - 234-41
AB  - BACKGROUND: Lifestyle changes have led to a high global incidence of type 2 
      Diabetes mellitus (T2DM). Evidence suggests beneficial effects of the intake of 
      n-3 and n-6 polyunsaturated fatty acids (PUFA) in patients with T2DM. OBJECTIVE: 
      To investigate the relationship between habitual fatty acid intake and 
      inflammatory biomarkers in Mexican individuals with and without T2DM. METHODS: A 
      cross-sectional study of 120 adults with and 120 without T2DM; anthropometric 
      assessments (BMI, waist circumference and body fat), blood pressure, PUFA intake, 
      biochemical analyses (glucose and lipid profile) and inflammation biomarkers 
      (IFN-gamma, TNF-alpha, IL-1 beta, IL-2, IL-6, IL-8 and IL-13) was undertaken. RESULTS: Low 
      n-3 intake was found in both groups (0.68 +/- 0.55g/day in T2DM vs 0.81 +/- 0.53 
      g/day in non-T2DM). Comparison between groups showed significantly higher 
      concentrations of triacylglcerols (p=.001) and IL-6 (p=.018) in the T2DM group, 
      as well as significant correlations between serum TNF-alpha and total n-3 fatty acid 
      intake (r=.507, p= .001), EPA (r=.284, p=.002), DHA (r=.404, p=.001), and a weak 
      but significant correlation between serum IL-1beta and total PUFA (r=.245, p=.005), 
      total n-3 (r=.214, p=.019) and total n-6 (r=.241, p=.008) intake. CONCLUSIONS: 
      Patients with T2DM had a tendency for higher pro-inflammatory cytokines than 
      subjects without T2DM. There was an association between PUFA intake and 
      pro-inflammatory biomarkers in patients with T2DM. Further studies of 
      anti-inflammatory nutrients and plasma and cell fatty acid profiles are needed to 
      corroborate the present findings in patients with and without T2DM.
FAU - Guadarrama-Lopez, Ana L
AU  - Guadarrama-Lopez AL
FAU - Valdes-Ramos, Roxana
AU  - Valdes-Ramos R
AD  - Center for Research and Graduate Studies in Health Sciences. Facultad de 
      Medicina, Universidad Autonoma del Estado de Mexico, Paseo Tollocan esq. Jesus 
      Carranza, Col. Moderna de la Cruz, Toluca, Edo, Mex, 50180 Mexico. 
      rvaldesr@uaemex.mx.
FAU - Kaufer-Horwitz, Martha
AU  - Kaufer-Horwitz M
FAU - Harbige, Laurence S
AU  - Harbige LS
FAU - Contreras, Irazu
AU  - Contreras I
FAU - Martinez-Carrillo, Beatriz E
AU  - Martinez-Carrillo BE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fatty Acids, Omega-6)
RN  - 0 (Fatty Acids, Unsaturated)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/*diet therapy/epidemiology
MH  - Early Diagnosis
MH  - Fatty Acids, Omega-3/*administration & dosage
MH  - Fatty Acids, Omega-6/*administration & dosage
MH  - Fatty Acids, Unsaturated/administration & dosage
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Male
MH  - Mexico/epidemiology
MH  - Middle Aged
EDAT- 2015/04/17 06:00
MHDA- 2016/06/25 06:00
CRDT- 2015/04/17 06:00
PHST- 2014/11/05 00:00 [received]
PHST- 2015/01/17 00:00 [revised]
PHST- 2015/04/03 00:00 [accepted]
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2016/06/25 06:00 [medline]
AID - EMIDDT-EPUB-66606 [pii]
AID - 10.2174/1871530315666150416130242 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2015;15(3):234-41. doi: 
      10.2174/1871530315666150416130242.